Andrade BS, Rangel FS, Santos NO, Freitas ADS, Soares WRA, Siqueira S, Barh D, Góes-Neto A, Birbrair A, Azevedo VAC. Repurposing approved drugs for guiding COVID-19 prophylaxis: a systematic review. Front Pharmacol. 2020 Dec 14;11:590598.
Callan N, Hanes D and Bradley R. Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain. J Transla Med 18:401. Oct 21, 2020.
Caly L, Druce JD, Catton MG, Jans DA and Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 178, 104787, June 2020.
Deire P, Caporuscio F, Saviano M, Mangiatordi GF. Repurposing known drugs as covalent and non-covalent inhibitors of the SARS-CoV-2 papain-like protease. Front Chem. Nov 16, 2020.
Gradišar, H, Keber MM, Pristovšek P and Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukocyte Biol 82, 968-974, 2007.
Hahn H, Kim S-J, Choi B-Y, Cho K-C, Bandu R, Kim KP, et al. Curcumin interacts directly with the cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells. Sci Rep. 8:6409; 2018.
Kory, P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Kronfeld H, Vinjevoll E, Mitchell S, Wagshul F, and Marik, PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. FLCCC Alliance; updated Jan 12, 2021.
Lescheid, David. Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses: a randomized, double-blind placebo-controlled study. Nutritional Fundamentals for Health, Inc. October 14, 2020.
Liu Z and Ying Y. The inhibitory effect of curcumin on virus-induced cytokine storm and its potential use in the associated severe pneumonia. Front Cell Dev Biol. 8:479.
Lu R, Zhai X, Li J, Nju P, Tang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. https://pubmed.ncbi.nlm.nih.gov/32007145/395, 5665-574.
Pinzi L, tinivella A, Caporuscio F and Rastelli G. Drug repurposing and polypharmacoloty to fight SARS-CoV-2 through inhibition of the main protease. Front. Pharmacol. Jan 12, 2021.
Polonikov, Alexey. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in patients with the novel coronavirus infection (COVID-19): a hypothesis based on literature data and own observations. ResearchGate. April 25, 2020.
Praditya D, Kurchhoff L, Brüning J, Rachmawati H, Steinmann J and Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol. 10:912, 2019.
Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ, Leblebicioglu H. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19). Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23.
Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013 Mar; 168(5);1059-1073.